Deals
Cubist Battling Superbugs Offers Remedy for J&J: Real M&A
This article is for subscribers only.
The timing may be right for a takeover of Cubist Pharmaceuticals Inc.
The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020 to combat bacterial infections that have become resistant to older therapies because of decades of overuse.